Medical treatment of intermittent claudication: a comparative double-blind study of suloctidil, dihydroergotoxine and placebo.
Forty-five patients suffering from intermittent claudication were admitted to a double-blind non-crossover study. Three groups were constituted at random and treated for 2 months with either 100 mg suloctidil t.i.d. or 1.5 mg dihydroergotoxine methylate t.i.d. or placebo. From the results of measurements of pain-free walking distance and venous occlusion plethysmography recordings, suloctidil was shown to be active and significantly superior to dehydroergotoxine and placebo: in the two latter groups a decrease in calf blood perfusion after 2 months was also noted. The physician's overall assessment of response to treatment showed that suloctidil and dihydroergotoxine were significantly superior to placebo, and that suloctidil was significantly better than dihydroergotoxine.
D000368:Aged; D002986:Clinical Trials as Topic; D004088:Dihydroergotoxine / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007383:Intermittent Claudication / Q000188:drug therapy*; D008297:Male; D011412:Propanolamines / Q000008:administration & dosage / Q000627:therapeutic use*
D011412:Propanolamines; D004088:Dihydroergotoxine